

lt's a Done Deal

\$17,000,000



PIPE

Sole Placement Agent

For more information please contact:

Investment Banking

James Antonopoulos Managing Director & Head of Healthcare Investment Banking (646) 358-1906 jantonopoulos@roth.com

Aparna Beeram Vice President (646) 358-1912 abeeram@roth.com

Equity Capital Markets

Aaron Gurewitz Head of Equity Capital Markets (949) 720-5703 agurewitz@roth.com

Nazan Akdeniz Senior Vice President

Roth Capital Partners Acted as Sole Agent for Creative Medical Technology (Nasdaq:CELZ) in its \$17 Million PIPE

Transaction Information

Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 7,555,556 shares of common stock (or common stock equivalents) in a private placement priced at-the-market under Nasdag rules. The Company will also issue to the investors unregistered warrants to purchase up to an aggregate of 15,111,112 shares of common stock. The purchase price for one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock is \$2.25. The warrants have an exercise price of \$2.00 per share, will be immediately exercisable, and will expire five years from issuance. The gross proceeds from the private placement are expected to be approximately \$17 million. The offering closed on May 3, 2022.

Roth Capital Partners acted as the sole placement agent for the offering.

(949) 720-5740 nakdeniz@roth.com

Lou Ellis Senior Vice President (949) 720-5739 Iellis@roth.com

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com.

About Roth Capital Partners

Roth Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, marketmaking services and corporate access. Headquartered in Newport Beach, CA, Roth is privately-held and employee owned, and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

About Roth | Investment Banking | Capital Markets | Institutional Sales & Trading Research | Corporate Services | Corporate Access & Conferences | Press Room

Date of Announcement: 5.16.22

The material, information and facts discussed in this announcement other than the information regarding Roth Capital Partners, LLC ("Roth") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2022.



ROTH Capital Partners, LLC

888 San Clemente Drive, Newport Beach CA, 92660 | Member SIPC / FINRA | www.roth.com